BioCardia

The momentum for this stock is not very good. BioCardia is not a good value stock. BioCardia is a mediocre stock to choose.

News

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Globe Newswire SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...\n more…

BioCardia prices 2.4M shares at $3.00 in upsized public offering

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Globe Newswire SUNNYVALE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...\n more…

Why BioCardia (BCDA) Stock Is Up 95% Today

Benzinga BioCardia shares are trading higher by 95% during Thursday's session. The FDA cleared the company to market its Morph DNA Steerable Introducer product family.\n more…

BioCardia shares climb as it gets FDA clearance for its Morph DNA product family

Seeking Alpha - Healthcare BioCardia shares climb as it gets FDA clearance for its Morph DNA product family...\n more…